Alterity Therapeutics (ATHE) Net Shares Issued and Repurchased (2015 - 2025)

Alterity Therapeutics' Net Shares Issued and Repurchased history runs 11 years deep, the most recent figure standing at $185.5 million for Q4 2025.

• On a quarterly basis, Net Shares Issued and Repurchased rose 26.9% year-over-year to $185.5 million in Q4 2025; TTM through Dec 2025 was $185.5 million, a 26.9% increase from a year earlier, with the FY2025 full-year figure at $168.4 million, up 14.51% from the prior year.
• Net Shares Issued and Repurchased grew to $185.5 million in Q4 2025 per ATHE's latest filing, from $168.4 million in the prior quarter.
• Across five years, Net Shares Issued and Repurchased topped out at $185.5 million in Q4 2025 and bottomed at $2.1 million in Q2 2023.
• The 5-year median for Net Shares Issued and Repurchased is $149.1 million (2021), against an average of $124.6 million.
• Across the five-year window, Net Shares Issued and Repurchased tumbled 98.6% in 2023 and soared 7446.46% in 2025, its largest moves.
• Year by year, Net Shares Issued and Repurchased stood at $155.8 million in 2021, then slipped by 9.81% to $140.5 million in 2022, then decreased by 0.39% to $139.9 million in 2023, then increased by 4.45% to $146.2 million in 2024, then gained by 26.9% to $185.5 million in 2025.
• Per Business Quant, the three latest ATHE Net Shares Issued and Repurchased figures stand at $185.5 million (Q4 2025), $168.4 million (Q2 2025), and $146.2 million (Q4 2024).